Whether the reduced ischemic risk from adding a novel oral anticoagulant (NOAC) to antiplatelets in patients with acute coronary syndromes (ACS) is worth the increased hazard from major bleeding may ...
Patients who are taking oral anticoagulation for atrial fibrillation and then undergo TAVR may be better off with a vitamin K antagonist (VKA) than with a non-VKA oral anticoagulant (NOAC), a registry ...
The efficacy and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) relative to warfarin do not substantially differ based on the presence of valvular heart disease, data from pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback